InsidersTradesSigma
Follow the GENELUX CORPORATION share price and the full insider trade history of the company, a listed equity based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Market capitalisation: €120.4m. The latest transaction was reported on 1 July 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: JOHN SMITHER. Every trade is free.
Analysts rate GENELUX CORPORATION Strong Buy (bullish), based on 6 analysts. Average price target: US$17.50.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
1 of 1 declaration
GENELUX CORPORATION is a company listed on the XNAS market, focused on developing gene therapies for cancer treatment.